Jeffrey Matous, MD, on the MonumenTAL-2 Study

By Jeffrey Matous, MD - Last Updated: December 13, 2023

Dr. Matous, a Member Physician at the Colorado Blood Cancer Institute in Denver and part of the Sarah Cannon Research Institute, shares results from the phase Ib MonumenTAL-2 study at the 65th American Society of Hematology Annual Meeting & Exposition.

Advertisement

The investigators studied the combination of talquetamab plus pomalidomide in patients with relapsed or refractory multiple myeloma.

“The results of the study, I think, are very impressive and in my mind demonstrate the most potent combination of pomalidomide with another agent that we’ve ever seen in clinical medicine before,” Dr. Matous said.

Post Tags:ASHNEWS2023
Advertisement
Advertisement
Advertisement
Editorial Board